We characterized the pharmacokinetic profile of imipenem-cilastatin administered intravenously to six normal volunteers in a dose of 1,000 mg of each drug every 6 h for 40 doses. The plasma concentrations of imipenem and cilastatin 1 h after the end of a 30-min infusion were 18.7 (± 2.1) and 19.1 (± 4.6), 20.0 (± 3.2) and 17.8 (± 4.8), and 23.4 (± 2.3) and 19.1 (± 3.5) ,ug/ml in the 1st, 17th, and 37th dosing intervals, respectively. The central compartment volumes of distribution for imipenem and cilastatin were 0.16 (± 0.05) and 0.14 (± 0.03) liter/kg, respectively. Elimination half-lives were short: 0.93 (± 0.09) h for imipenem and 0.84 (± 0.11) h for cilastatin. Plasma clearances were 12.1 (± 0.06) liters/h per 1.73 m2 for imipenem and 12.4 (± 1.1) liters/h per 1.73 m2 for cilastatin. Renal clearance accounted for 54% of the plasma clearance of imipenem and 69% of the plasma clearance of cilastatin. Sample acquisition and assay. Blood samples from all volunteers were collected during the 1st, 17th, and 37th dosing intervals before the dose, at the termination of the half-hour infusion, and at 0.25, 0.5, 0.75, 1, 1.5, 2.5, 3.5, 4.5, and 5.5 80 [Lg/ml; the coefficient of variation was 0.28% at 96.1 ,ug/ ml, 5.2% at 53.8 pLg/ml, and 4.7% at 2.6 ,ug/ml. Cilastatin was assayed by the high-pressure liquid chromatographic technique described by Demetriadis et al. (personal communication). The plasma assay was linear over a range from 0.75 to 75 ,ug/ml; the coefficient of variation was 3.7% at 75 pLg/ml, 3.0% at 50 Fg/ml, 2.6% at 20 jLg/ml, 2.2% at 10 [ig/ml, 2.5% at 5 ,ug/ml, 2.6% at 2 [ig/ml, 10.5% at 1 p.g/ml, and 10% at 0.75 p.g/ml.
Imipenem is the first member of a new class of beta-lactam antibiotics, the carbapenems, to become clinically available. In vitro studies have shown activity against Enterobacteriaceae, Pseudomonas aeruginosa, and anaerobes including Bacteroidesfragilis, and activity against gram-positive cocci including Staphylococcus aureus and the enterococci has been retained (1, 8, 11) . However, the urinary recovery of imipenem in animals and human volunteers has been low and far below the glomerular filtration rate for each species. Further, in toxicology studies conducted at Merck Sharp & Dohme Research Laboratories, it was discovered that imipenem administered alone to rabbits caused proximal tubular necrosis similar to that produced by cephaloridine (6) . The renal dehydropeptidase-I inhibitor, cilastatin, prevented these histological changes and enhanced the urinary recovery of imipenem even when both drugs were administered in high doses for a prolonged period of time. Consequently, we examined the pharmacokinetics of imipenem and cilastatin in volunteers receiving 1,000 mg of each drug intravenously every 6 h for 40 doses. This is a dose and schedule likely to be used for critically ill patients.
MATERIALS AND METHODS
Subjects. Twelve healthy male volunteers were recruited and housed for 14 days in a restricted-access research ward. Written 75 ,ug/ml; the coefficient of variation was 3.7% at 75 pLg/ml, 3 .0% at 50 Fg/ml, 2.6% at 20 jLg/ml, 2.2% at 10 [ig/ml, 2.5% at 5 ,ug/ml, 2.6% at 2 [ig/ml, 10.5% at 1 p.g/ml, and 10% at ANTIMICROB. AGENTS CHEMOTHER. Renal clearances were determined as the amount of imipenem excreted in the urine divided by the plasma area under the curve for the collection period (4) . Table 1 . The mean plasma concentrations immediately after the end of the halfhour infusion were 52.1 ± 13.8, 57.4 ± 8.1, and 66.9 ± 9.2 ,ug/ml for the 1st, 17th, and 37th dosing intervals, respectively. At 1 h, the first dosing interval showed a mean level of 18.7 ± 2.1 ,ug/ml, the 17th dosing interval was 20.0 ± 3.2 ,ug/ml, and the 37th dosing interval was 23.4 + 2.3 ,uglml. At trough, values were 0.8 ± 0.26, 1.0 ± 0.34, and 1.3 ± 0.15 ,ug/ml, respectively, for the same dosing intervals.
The mean pharmacokinetic parameters of imipenem determined from all of the data points simultaneously modeled are shown in Table 2 . The volume terms were consistent with a drug that distributes essentially into the extracellular fluid. The mean terminal excretion half-life of ca. 1 h was short and similar to that of many penicillins. The mean plasma clearance was 12.1 liters/h per 1.73 M2. It should be noted that the data from two of the volunteers were adequately described by a one-compartment model (Table 2) . and 37th dosing intervals (P < 0.02 by Student's paired t test). There were no statistically significant differences between plasma clearances during the 1st and the 17th dosing intervals. There were no changes in creatinine clearance or hepatic function indices that would explain the decreased apparent plasma clearance (data not shown).
Because one mechanism to explain this phenomenon is slow deep tissue accumulation, these data were analyzed by utilizing a three-compartment open model. In five of the six subjects, these fits were better than those obtained with a one-or two-compartment model. However, examination of the residual plots revealed that not all of the observed change in apparent plasma clearance could be accounted for even by a three-compartment model.
Urinary excretion of imipenem. The mean urinary concentrations of imipenem and cumulative renal excretion are shown in Table 4 . These values are particularly relevant in evaluating imipenem as an agent for serious urinary tract infections. The lowest value observed was 73.2 pug/ml, which occurred in a 4-to 6-h collection. This value is 20 times the 90% MICs for the most resistant urinary tract pathogens (1, 8, 11) .
Renal elimination of unchanged drug accounted for slightly more than half of the total plasma clearance. The fraction of the remaining plasma clearance accounted for by metabolic transformation in the renal tubule by dehydropeptidase I is unknown. Metabolic biotransformation outside the kidney has not been described but could also contribute to nonrenal clearance.
Plasma pharmacokinetics of cilastatin. The mean plasma concentrations (± standard deviation) of cilastatin for the 1st, 17th, and 37th dosing intervals are shown in Fig. lb . Individual patient data are shown in Table 5 . The mean plasma concentrations immediately after the end of the halfhour infusion were 65.0 ± 14.7, 65.2 ± 11.6, and 64.4 ± 8.5 pg/ml for the 1st, 17th, and 37th dosing intervals, respectively. At 1 h postinfusion, the 1st dosing interval showed a mean concentration of 19.1 ± 4.6 ,ug/ml; the 17th dosing interval, 17.8 ± 4.8 jig/ml, and the 37th dosing interval, 19.1 ± 3.5 ,ug/ml. At 4.5 h postinfusion, these values were 1.56 ± 0.63, 0.94 ± 0.65, and 0.99 ± 0.16 pug/ml, respectively. The majority of 5.5-h plasma levels were less than the 0.75-,ug/ml limit of sensitivity. The mean pharmacokinetic parameters determined by the model-dependent technique are shown in should be noted that these parameters were determined for both drugs simultaneously in the same subjects, and consequently the similarity of behavior for these two drugs was striking. There was no trend for change in the apparent plasma clearance with time for cilastatin.
Urinary excretion of cilastatin. The first-dose cumulative renal excretion of cilastatin is shown in Table 7 . Renal elimination of unchanged drug accounted for ca. 70% of the total plasma clearance. DISCUSSION Kropp and his colleagues were able to demonstrate renal metabolism of imipenem by a dehydropeptidase I enzyme resulting in low urinary recoveries in animal species (7) . Work at Merck Sharp & Dohme has demonstrated that imipenem, when administered alone in the rabbit animal model, produces histological changes in the kidney approximately equivalent in severity to that seen with cephaloridine (6) .
Cilastatin is the sodium salt of a derivatized heptenoic acid and has a molecular weight of ca. 380. This compound, which has no intrinsic antimicrobial activity, inhibits dehydropeptid,ase I, a zinc metalloenzyme located on the brush border of the renal tubule. Co-administration of imipenem and cilastatin has been shown to prevent proximal tubular necrosis in the rabbit model (6) . Furthermore, in a volunteer study, Norrby and his colleagues were able to demonstrate a significant increase in the plasma area under the curve as well as increased urinary recovery of imipenem with coadministration of cilastatin (9) .
In analyzing the available pharmacological information for imipenem-cilastatin, we found that the pharmacokinetics of cilastatin observed in the study were similar to those of imipenem. The actual plasma concentrations obtained, the volumes of distribution, and the plasma clearances for both compounds were similar. We observed one minor difference in the pharmacokinetics of the two compounds. Fifty-four percent of the plasma clearance of imipenem was accounted for by renal clearance, compared with 69% of the plasma clearance for cilastatin. This difference might lead one to assume that, with increasing degrees of renal dysfunction, the observed plasma concentrations of cilastatin may increase slightly out of proportion to that observed for imipenem. If this should occur, it should not present a major problem as cilastatin has proved to be nontoxic in animal studies (J. McDonald, Merck Sharp & Dohme, personal communication), and the higher plasma concentrations should only provide better inhibition of the dehydropeptidase I enzyme.
The time course of imipenem in the plasma of our volunteers was such that, with the antimicrobial activity of this compound, coverage should be provided for all common gram-positive and gram-negative bacterial pathogens with the possible exception of a minority of P. aeruginosa and members of the tribe Proteeae. The pharmacokinetic parameters derived from the plasma concentrations resembled those of other beta-lactams in that imipenem distributed into volumes equivalent to the extracellular fluid volume. Its terminal elimination half-life, as observed in normal volunteers, was short-ca. 1 h-again consonant with the behav- ior of many other beta-lactams, particularly the penicillins. that this effect only became manifest after day 5 of multiple Our pharmacokinetic parameter values, particularly those dosing. Finally, we may merely be observing the day-to-day reported in'the evaluation of the first dose, were quite similar biological variation in our' system, although the consistency to those reported by Norrby and his colleagues (10) . Howevof the change among the volunteers mitigated against this er, in analyzing the multiple-dose trial, it became apparent explanation. that the plasma concentrations during the 37th dosing interWe cannot distinguish between possible hypotheses with val were systematically underpredicted by two-compartment the available data, but if the three-compartment model with analysis of data from the 1st plus 17th intervals. Modeldeep tissue accumulation explanation is the correct one, low independent determination of the apparent plasma clearance levels of imipenem should be observable in the serum for of imipenem for the 1st, 17th, and 37th dosing intervals relatively long periods after the termination of multiple-dose revealed a statistically significant decrease noted by the 37th administration. Preliminary data obtained from patients redosing 'interval compared with the 1st and 17th dosing ceiving 1,000 mg of imipenem plus enzyme inhibitor in intervals. Norrby and his colleagues did not note this decline clinical trials at the Hospital of the University of Pennsylvain plasma clearance during their multiple-dose trial of iminia, Philadelphia, under the direction of Rob Roy McGregor penem. It should be borne i'n mind, however, that we also have not been consistent with this prediction. Whatever the did not note any change in the plasma clearance between the correct explanation for the observed phenQmenon, it is not 1st and 17th doses, i.e., between the days 1 and 5. Norrby's of a degree that should be' clinically' significant. study lasted 3 to 4 days and, consequently, the lack of The renal clearance of imipenem seen in this study was change in clearance is consistent with our findings. Blecause slightly lower 'than that seen in the study of Norrby and of the decline in apparent clearance, the data were also colleagues (9) 
